LSD shows promise for anxiety in new clinical trial
NCT ID NCT05407064
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 study tested four different doses of MM120 (a form of LSD) against a placebo in 198 people with generalized anxiety disorder. The goal was to see which dose best reduces anxiety symptoms over 4 to 8 weeks. Participants took a single dose and were monitored for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MM120 (LSD D-Tartrate)
- What this could lead to
- If successful, this could point toward a new treatment option for generalized anxiety disorder using a controlled dose of LSD.
- What could go wrong
- This is an early Phase 2 study with only 198 participants. The results may not apply to everyone, and LSD can cause intense psychological effects and risks like anxiety or confusion during the session.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANXIETY, GENERALIZED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adams Clinical
Watertown, Massachusetts, 02472, United States
-
BioBehavioral Research of Austin
Austin, Texas, 78759, United States
-
CNS Healthcare - Orlando
Orlando, Florida, 32801, United States
-
Cedar Clinical Research
Draper, Utah, 84020, United States
-
Cedar Clinical Research - Murray
Murray, Utah, 84107, United States
-
GMI - Princeton Medical Institute
Princeton, New Jersey, 08540, United States
-
Great Lakes Clinical Trials
Chicago, Illinois, 60640, United States
-
Hassman Research Institute
Berlin, New Jersey, 08009, United States
-
Irvine Center for Clinical Research
Irvine, California, 92614, United States
-
Kadima Neuropsychiatry Institute
La Jolla, California, 92037, United States
-
Lutheran Hospital - Cleveland Clinic
Cleveland, Ohio, 44113, United States
-
Mountain View Clinical Research
Denver, Colorado, 80209, United States
-
Pacific Neuroscience Institute
Santa Monica, California, 90404, United States
-
Preferred Research Partners
Little Rock, Arkansas, 72211, United States
-
SISU
Springfield, Massachusetts, 01103, United States
-
Segal Trials
Lauderhill, Florida, 33319, United States
-
Sunstone Therapies
Rockville, Maryland, 20850, United States
-
University of Texas Health Houston
Houston, Texas, 77054, United States
-
Uptown Research
Chicago, Illinois, 60640, United States
-
Wholeness Center
Fort Collins, Colorado, 80525, United States
-
Woodstock Research Center
Woodstock, Vermont, 05091, United States
-
iResearch Atlanta
Decatur, Georgia, 30030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.